United Kingdom Breast Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Breast Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
The United Kingdom Breast Cancer Therapeutics Market is poised for significant growth in the projected period of 2028. Breast cancer continues to be a major public health concern in the United Kingdom, posing challenges for individuals, medical professionals, and researchers alike. However, advancements in breast cancer therapies have led to more effective treatment options and improved quality of life for patients. The United Kingdom boasts a robust healthcare system, particularly one that prioritizes breast cancer care.
Breast cancer is characterized by the uncontrolled proliferation of cells in the breast. There are various forms of breast cancer, with the type determined by the specific cells involved. Different regions of the breast can be affected by breast cancer, which consists of connective tissue, ducts, and lobules. Lobules are responsible for milk production, while milk is transported through ducts to the nipple. Connective tissue provides support and envelops the structures of the breast. Most breast cancers originate in the ducts or lobules.
The United Kingdom's breast cancer therapeutics market is projected to experience substantial growth in the coming years. Factors such as increasing disease prevalence, growing awareness, and advancements in treatment options are driving market expansion. Moreover, collaborations between academic institutions, research organizations, and pharmaceutical companies are fostering innovation and accelerating the development of novel therapies. The field of breast cancer research is continuously evolving, with several promising therapies currently in development. These include antibody-drug conjugates, PARP inhibitors, and PI3K inhibitors, among others. These innovative therapies specifically target vulnerabilities in breast cancer cells and hold potential for further enhancing patient outcomes, particularly in cases that are resistant or advanced, thus contributing to the growth of the United Kingdom Breast Cancer Therapeutics Market.
Another significant advancement in breast cancer therapeutics is the emergence of immunotherapy. Immune checkpoint inhibitors, such as pembrolizumab, have shown promising results in patients with advanced triple-negative breast cancer, a subtype that has traditionally been challenging to treat. Immunotherapies harness the body's immune system to recognize and eliminate cancer cells, offering new hope to patients who previously had limited treatment options. This is expected to drive the growth of the United Kingdom Breast Cancer Therapeutics Market.
Rising Prevalence of Breast Cancer Will Spur the Demand for Breast Cancer Therapeutics
The United Kingdom is faced with a significant burden of breast cancer, a devastating disease that claims numerous lives annually. Among women in the United Kingdom, breast cancer is the most prevalent form of cancer, with its incidence steadily increasing. This rise in breast cancer cases has driven the growth of the United Kingdom Breast Cancer Therapeutics Market, as healthcare providers and pharmaceutical companies strive to develop innovative treatments and improve patient outcomes. Several factors, including an aging population, changing lifestyle patterns, and improved screening and diagnostic methods, have contributed to better detection and reporting of breast cancer cases. According to the International Agency for Research on Cancer, there were 53,889 new cases of breast cancer reported in the United Kingdom in 2020, accounting for 11.8% of all new cancer cases, totaling 457,960. While multiple factors contribute to the development of breast cancer, an unhealthy lifestyle remains a significant driver. Exposure to the drug diethylstilbestrol (DES) remains the primary cause of breast cancer, and the high rates of obesity in the United Kingdom further exacerbate the problem, as excess body weight is associated with an elevated risk of breast cancer. The link between diet, obesity, and breast cancer underscores the need for therapeutics to manage and treat the disease. According to NHS Digital, 25.9% of adults in England are obese, and an additional 37.9% are overweight but not obese, with obesity defined as having a body mass index (BMI) of 30 or above. While lifestyle choices play a significant role in the development of breast cancer, environmental factors should not be overlooked. Women who experience menstruation before the age of 12 and menopause after the age of 55 are exposed to hormones for a longer period, increasing their risk of developing breast cancer and contributing to the expansion of the United Kingdom Breast Cancer Therapeutics Market. Moreover, awareness campaigns and initiatives by organizations and healthcare providers have played a crucial role in promoting early detection of breast cancer in the United Kingdom. Public awareness programs, including breast self-examination campaigns and routine mammography screenings, have contributed to the identification of breast cancer at earlier stages, allowing for more effective treatment interventions and increasing the chances of successful outcomes. According to the Office for National Statistics, the estimated healthcare cost in the UK was USD 350.83 billion in 2022, representing a nominal increase of 0.7% compared to 2021.
Expanding Revolutionary New Technology Drives the United Kingdom Breast Cancer Therapeutics Market
In the United Kingdom, significant progress has been made in the battle against breast cancer, particularly with the emergence of advanced radiation techniques. The development of targeted therapies, specifically immune checkpoint inhibitors and antibody-drug conjugates, has garnered tremendous attention in fighting breast cancer, revolutionizing its treatment. These cutting-edge treatments offer new hope to patients, propelling the growth of the United Kingdom Breast Cancer Therapeutics Market.
Immune checkpoint inhibitors, a class of drugs that assist the body's immune system in recognizing and attacking cancer cells, play a crucial role in this fight. By blocking the proteins that hinder immune cells from identifying and eliminating cancer cells, these drugs demonstrate their efficacy in treating breast cancer. Multiple clinical trials are currently ongoing in the United Kingdom to assess the safety, effectiveness, and potential of immune checkpoint inhibitors in breast cancer treatment. The outcomes of these trials are expected to enhance patient outcomes and contribute to the growth of the United Kingdom Breast Cancer Therapeutics Market.
The introduction of these novel technologies has significantly impacted the United Kingdom Breast Cancer Therapeutics Market. The availability of targeted therapies has opened up new avenues for personalized and precision medicine, providing patients with tailored treatment options based on their tumor characteristics. Furthermore, these advancements have the potential to improve patient outcomes by increasing response rates and extending survival.
In response to this progress, the United Kingdom has witnessed a surge in investments and research collaborations focused on developing and commercializing these innovative treatments. Pharmaceutical companies, biotechnology firms, and research institutions are actively engaged in clinical trials and the development of new drug candidates, aiming to bring these therapies to market. This increased research and development activity has fostered competition among market players, driving innovation and fueling the growth of the breast cancer therapeutics market in the United Kingdom.
Moreover, the introduction of novel technologies has spurred advancements in diagnostic techniques, enabling early detection and better patient stratification. The integration of biomarkers and genetic testing has facilitated the identification of patients who are most likely to benefit from these targeted therapies. This approach not only optimizes treatment outcomes but also helps reduce healthcare costs by avoiding ineffective treatments.
Recent Developments
- In March 2023, Novartis AG NVS released positive top-line results from an interim analysis of the late-stage NATALEE study on the breast cancer medication Kisqali.
- In May 2023, Dr Anita Grigoriadis, from King’s College London, created a system to estimate the risk of cancer spreading by keeping an eye out for early changes in the lymph nodes under the armpit. For women with triple-negative breast cancer, of which there are about 8,000 per year, it can be used in the very early stages of the disease. AI can predict what a cancer will most likely do next by comparing a woman's lymph nodes to those of previous patients.
Market Segmentation
The United Kingdom Breast Cancer Therapeutics Market is classified into Therapy, End User, and company. In terms of Therapy, the market is segmented into Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, and Others. The End User segment includes Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. Geographically, the market is divided into Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
Novartis AG, Pfizer Inc, Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eisai Co., Ltd., Sanofi S.A., Mylan NV are some of the key players of United Kingdom Breast Cancer Therapeutics market.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, company shares, competitive landscape, growth factors, and trends |
Segments covered | Therapy End User Region |
Country scope | Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands |
Key companies profiled | Novartis AG, Pfizer Inc, Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eisai Co., Ltd., Sanofi S.A., Mylan NV |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy